[go: up one dir, main page]

TW200637546A - Combination therapy - Google Patents

Combination therapy

Info

Publication number
TW200637546A
TW200637546A TW094144909A TW94144909A TW200637546A TW 200637546 A TW200637546 A TW 200637546A TW 094144909 A TW094144909 A TW 094144909A TW 94144909 A TW94144909 A TW 94144909A TW 200637546 A TW200637546 A TW 200637546A
Authority
TW
Taiwan
Prior art keywords
hydrochlorothiazide
combination therapy
telmisartan
angiotensin
treatment
Prior art date
Application number
TW094144909A
Other languages
Chinese (zh)
Inventor
Helmut E Schumacher
Axel Riedel
Peter Boehm
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200637546(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200637546A publication Critical patent/TW200637546A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition comprising about 80 mg telmisartan and about 25 mg hydrochlorothiazide or about 160 mg telmisartan and about 50 mg hydrochlorothiazide for the treatment of hypertension in patients with an insufficient blood pressure reduction upon treatment either with an angiotensin II receptor antagonist, or a pharmaceutical composition of an angiotensin II receptor antagonist and a low dose of hydrochlorothiazide.
TW094144909A 2004-12-17 2005-12-16 Combination therapy TW200637546A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
TW200637546A true TW200637546A (en) 2006-11-01

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094144909A TW200637546A (en) 2004-12-17 2005-12-16 Combination therapy

Country Status (15)

Country Link
EP (1) EP1827424A1 (en)
JP (1) JP2008524136A (en)
KR (1) KR20070097511A (en)
CN (1) CN101080225A (en)
AR (1) AR052052A1 (en)
AU (1) AU2005315855A1 (en)
BR (1) BRPI0519656A2 (en)
CA (1) CA2589493A1 (en)
EA (1) EA200701159A1 (en)
IL (1) IL183944A0 (en)
NO (1) NO20072325L (en)
PE (1) PE20060768A1 (en)
TW (1) TW200637546A (en)
UY (1) UY29274A1 (en)
WO (1) WO2006063737A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
CA2702904A1 (en) * 2007-10-19 2009-04-23 Otsuka Pharmaceutical Co., Ltd. Matrix-type pharmaceutical solid preparation
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
WO2009115301A1 (en) 2008-03-19 2009-09-24 Ratiopharm Gmbh Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
KR20110038145A (en) 2008-07-31 2011-04-13 다케다 야쿠힌 고교 가부시키가이샤 Solid Pharmaceutical Compositions
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
HRP20130557T1 (en) 2009-06-19 2013-07-31 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
EP2448576A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
WO2011002425A2 (en) * 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (en) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Solid dosage forms containing telmisartan.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
EP2952196A4 (en) * 2013-01-31 2016-08-03 Sawai Seiyaku Kk MULTILAYER TABLET CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE
ES2847904T3 (en) 2013-07-23 2021-08-04 Daiichi Sankyo Co Ltd Medicine for the prevention or treatment of hypertension
CN106562973A (en) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 Anti-hypertension medicine compound preparation
CN107501192A (en) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 The eutectic of Telmisartan and Hydrochioro
CN108653227A (en) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 A kind of Telmisartan hydrochlorothiazide tablets and preparation method thereof
EP4029867A1 (en) * 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (en) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Elongated, divisible tablet
ES2298351T5 (en) * 2002-01-16 2012-01-26 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG METHOD FOR PRODUCING A TWO-LAYER PHARMACEUTICAL TABLET THAT INCLUDES TELMISARTAN AND HYDROCLOROTIAZIDA.

Also Published As

Publication number Publication date
EA200701159A1 (en) 2007-12-28
IL183944A0 (en) 2007-10-31
PE20060768A1 (en) 2006-09-29
CA2589493A1 (en) 2006-06-22
BRPI0519656A2 (en) 2009-03-03
EP1827424A1 (en) 2007-09-05
UY29274A1 (en) 2006-07-31
KR20070097511A (en) 2007-10-04
AU2005315855A1 (en) 2006-06-22
AR052052A1 (en) 2007-02-28
CN101080225A (en) 2007-11-28
WO2006063737A1 (en) 2006-06-22
NO20072325L (en) 2007-07-06
JP2008524136A (en) 2008-07-10

Similar Documents

Publication Publication Date Title
TW200637546A (en) Combination therapy
IL273765A (en) Combinations and modes of administration of therapeutic agents and combination therapy
UA101309C2 (en) Activin-actrii antagonists thereof and uses for increasing red blood cell levels
AU2003210300A1 (en) The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure
EP2248519A3 (en) Non-mucoadhesive film dosage forms
WO2004010975A3 (en) Controlled drug delivery
NO20072931L (en) Improved dosing regimen of temozolomide for the treatment of cancer based on the patient's MGMT level
WO2005048850A3 (en) Systems and methods relating to associating a medical implant with a delivery device
EP2335727A3 (en) Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
LU93321I2 (en) IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO2004087011A3 (en) Therapeutic agent delivery device with controlled therapeutic agent release rates
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
WO2007146426A3 (en) Nanoshells for drug delivery
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
WO2004064734A3 (en) Combination therapies for the treatment of cancer
CY1112184T1 (en) PYRIDOXAMINE FOR USE IN TREATMENT OF DIABETIC Nephropathy in Type II Diabetes
BRPI0413974A (en) combination, method of treating cancer in a warm-blooded animal, pharmaceutical composition, and, use of a combination
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
MY137620A (en) Therapeutic treatment
BRPI0510895A (en) 10-propargyl-10-deazaaminopterin pharmaceutical formulation for t-cell lymphoma treatment
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
TW200501953A (en) Combination therapy for hypertension using lercanidipine and an angiotensin II receptor blocker
TW200509909A (en) Use of organic compounds
WO2009134056A3 (en) Pharmaceutical formulation